Neonatal purpura fulminans
Bubl B, Gysling Hagemann K, Dallavès F, Bartenstein A, Nelle M, Neonatology (BB, NM), Hematology/Oncology (GHK), Human Genetics (DF), Pediatric Surgery (BA), University Children’s Hospital of Berne, Switzerland

Title figure:
Molecular structure of protein C
(Source: www.wikipedia.com)
The PROC-gene is located on chromosome 2q13-q14 and encodes a vitamin K-dependent glycoprotein (1). Protein C (PC) is a zymogen produced by the liver; it is activated when it binds to thrombin. Activated protein C (APC) is a serine protease and has three main functions, two of which concern the coagulation system. First, APC is a very important inhibitor of the coagulation cascade by cleaving and inhibiting activated coagulation co-factors FVa and FVIIIa. Secondly, APC enhances fibrinolysis by inhibiting plasminogen activator inhibitor-1 (PAI-1). In addition, APC has cytoprotective and anti-inflammatory effects.

In PC deficiency, decreased inhibition results in thrombus formation and reduced fibrinolysis. PC deficiency is diagnosed directly by an immunological quantitative method (norm: 65–150%). A functional assay uses the activated partial thromboplastin time (aPTT) (norm: 70–120%) (2). Newborns physiologically have a lower activity of 17–53%; activity increases with advancing degree of maturation.

Acquired PC deficiency must be differentiated from congenital PC deficiency, which is inherited in an autosomal recessive manner. In its heterozygous presentation, it is mostly asymptomatic during the neonatal period. Homozygous or compound heterozygous forms are associated with development of purpura fulminans (3), as well as intravitreal and intracerebral hemorrhages (4). The latter two symptoms may
manifest prenatally (5). In most cases, purpura fulminans, which is caused by dermal microvascular thrombosis, emerges within 2–12 hours after birth. As purpura fulminans develops, skin changes progress from deep-red into purple lesions. These lesions quickly become darker and develop black crusts. They predominantly are observed on the extremities (thighs) and the buttocks (6). Histology is characterized by involvement of small vessels at the junction of dermis and subcutaneous fat with intraluminal thrombi, sparse perivascular infiltrates of neutrophils, extravasated erythrocytes, edema of the dermis and epidermal necrosis with subepidermal blister formation.

The diagnosis of PC deficiency is made when absence of protein C in plasma combined with elevated D-dimers can be demonstrated in patients with a typical clinical presentation. In addition, disseminated intravascular coagulation (DIC) can lead to thrombocytopenia, low levels of fibrinogen or other coagulation factors. Genetic analysis is essential to establish the diagnosis of congenital PC deficiency. There are two different types of this disorder. The more common type I is characterized by a reduced protein concentration (i.e., quantitative deficiency). In type II, on the other hand, protein function is reduced (i.e., qualitative deficiency). Homozygous or compound heterozygous PC deficiency is rare with an incidence of 1:500'000 – 1:750'000 (7).
Acquired PC deficiency in the neonate results from increased consumption and can be seen in severe group B streptococcus infection (8). Other cases of acquired PC deficiency are secondary to reduced hepatic production, for example in galactosemia, during warfarin therapy or because of immaturity of the liver.
At 28 weeks of pregnancy, prenatal ultrasound examination demonstrated bilateral hydrocephalus in a male infant. This was confirmed by fetal MRI; in addition, bilateral grade IV periventricular/intraventricular hemorrhages were demonstrated.

Because of these findings, the infant was delivered by elective Cesarean section at 39 weeks of gestation. Adaptation was uneventful. However, within a few hours after birth, rapidly progressive skin lesions consistent with purpura fulminans developed on his buttocks and thighs (Fig. 1–4), as well as on his left lower leg. While the platelet count was normal, coagulation studies were mildly abnormal with a Quick value of 34% and an aPTT of 54.5 s. On extended coagulation studies, complete absence of PC was demonstrated. On genetic testing, he was found to be compound heterozygous for two disease-causing mutations in the PROC-gene. Additionally, a factor V Leiden mutation was found.

On neurological examination, the infant was hypotonic with periods of agitation. Both conventional EEG and aEEG were physiological. On cranial ultrasound examinations, non-progressive post-hemorrhagic hydrocephalus was confirmed. In addition, bilateral vitreous and retinal hemorrhages were seen on fundoscopy.

After initial administration of fresh frozen plasma, intravenous PC concentrate (Ceprotin®, Baxter) was
Early skin changes in the left groin region a few hours after birth.
Rapid progression of purpura fulminans: appearance of the skin on the left thigh at 24 hours of age.
Rapid progression of purpura fulminans: appearance of the skin on the buttocks at 24 hours of age
Rapid progression of purpura fulminans: appearance of the skin on the buttocks at 48 hours of age.
started. With this treatment, there was no further progression of the purpuric lesions, and the skin began to heal (Fig. 5, 6). Dosing of PC concentrate therapy was based on aPTT measurements. On one occasion, when the PC activity measured by the aPTT method fell below 30%, swelling of the legs and worsening of ventilation were noted. Thrombotic and thromboembolic events were excluded, and increased dosing of PC concentrate was followed by clinical improvement.

The challenging transition from intravenous to subcutaneous injections was managed well without complications. With a subcutaneous dose of 200 E/kg/d PC concentrate twice daily appropriate PC blood levels were measured. The infant was discharged home at the age of two months.
Improvement of skin changes on day of life 8 after treatment with PC replacement.
At 28 days of life, the purpura fulminans lesions have healed almost completely.
Early recognition and diagnosis, followed by rapid therapeutic intervention are extremely important in patients with pupura fulminans. In cases of acquired PC deficiency, the underlying causes must be uncovered and treated promptly. Symptomatic emergency treatment with intravenous fresh frozen plasma followed by PC concentrate is identical for both acquired and inherited forms of PC deficiency (9).

For long-term therapy of severe PC deficiency, oral anticoagulation with warfarin is still used most commonly. However, adequate dosing can be challenging in small children (10). More recently, substitution of PC concentrate – if available – has become the treatment of choice. Obtaining and maintaining long-term vascular access can be difficult and catheter-associated complications are common. Administration of protein C concentrate via the subcutaneous route was first described by Minford et al. in 1996 (11). Other reports followed (10,12–14). Based on these encouraging reports, we decided to switch our patient from intravenous to subcutaneous PC replacement therapy prior to discharge home. A PC dose of 200 U/kg/day (slightly below the recommended 250 U/kg/day published in the literature) (15), resulted in adequate PC levels (> 30% measured by the aPTT method) without increase of D-dimers.

In 2009, Lee et al. described a six-month-old girl with homozygous protein C deficiency who was success-
fully treated with living donor liver transplantation. They suggested that liver transplantation might be an alternative and curative treatment for children with homozygous protein C deficiency (16).
Our patient with a compound heterozygous mutation in the PROC-gene presented with the typical clinical triad of periventricular/intraventricular hemorrhage, purpura fulminans, and vitreous hemorrhage. Rapid diagnosis and therapy of congenital PC deficiency with fresh frozen plasma and PC concentrate are essential. For long-term therapy, subcutaneous administration of PC concentrate appears to be a reliable and safe method.


